Stockholders' Equity Note Disclosure [Text Block] | 6 Share capital Authorized: unlimited common shares, no par value in thousands of dollars, except share amounts Number of shares Ascribed value $ November 30, 2017 105,684,523 136,525 Bought deal financing 24,784,482 28,750 Share issuance costs - (1,805 ) Exercise of options 315,148 140 Restricted Share Units 800,000 457 NovaGold DSU Conversion 1,459 2 November 30, 2018 131,585,612 164,069 Exercise of options 44,230 28 Restricted Share Units 412,501 424 February 28, 2019, issued and outstanding 132,042,343 164,521 On April 30, 2012, under the NovaGold Arrangement, Trilogy committed to issue common shares to satisfy holders of NovaGold deferred share units (“NovaGold DSUs”) on record as of the close of business April 27, 2012. When vested, Trilogy committed to deliver one Common Share to the holder for every six shares of NovaGold the holder is entitled to receive, rounded down to the nearest whole number. As of February 28, 2019, there remains 11,927 NovaGold DSUs outstanding representing a right to receive 1,988 Common Shares in Trilogy, which will settle upon certain directors retiring from NovaGold’s board. (a) Stock options During the period ended February 28, 2019, the Company granted 2,430,000 options (2018 – 2,125,000 options) at a weighted-average exercise price of CAD$2.94 (2018 – CAD$1.04) to employees, consultants and directors exercisable for a period of five years with various vesting terms from immediate vesting to over a two-year period. The weighted-average fair value attributable to options granted in the period was $1.08 (2018 - $0.37). For the period ended February 28, 2019, Trilogy recognized a stock-based compensation charge of $1.59 million (2018– $0.49 million) for options granted to directors, employees and service providers, net of estimated forfeitures. The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model for the period are as provided below. February 28, 2019 Risk-free interest rates 2.05 % Exercise price CAD$ 2.92 Expected life 3.0 years Expected volatility 75.4 % Expected dividends Nil As of February 28, 2019, there were 1,835,006 non-vested options outstanding with a weighted average exercise price of $1.80; the non-vested stock option expense not yet recognized was $1.13 million. This expense is expected to be recognized over the next two years. A summary of the Company’s stock option plan and changes during the period ended February 28, 2019 is as follows: February 28, 2019 Number of options Weighted average exercise price $ Balance – beginning of the period 8,821,434 0.60 Granted 2,430,000 2.23 Exercised (73,334 ) 0.81 Balance – end of period 11,178,100 0.96 The following table summarizes information about the stock options outstanding at February 28, 2019. Outstanding Exercisable Unvested Range of price Number of outstanding options Weighted average years to expiry Weighted average exercise price $ Number of exercisable options Weighted average exercise price $ Number of unvested options $0.33 to $0.50 3,996,433 1.46 0.39 3,996,433 0.39 - $0.51 to $1.00 4,406,667 2.67 0.73 3,924,997 0.73 481,670 $1.01 to $1.50 225,000 4.12 1.34 125,000 1.25 100,000 $1.51 to $2.00 120,000 4.36 1.84 86,666 1.81 33,334 $2.01 to $2.23 2,430,000 4.76 2.23 1,209,998 2.23 1,220,002 11,178,100 2.74 0.96 9,343,094 0.80 1,835,006 The aggregate intrinsic value of vested share options (the market value less the exercise price) at February 28, 2019 was $13 million (2019 - $6.9 million) and the aggregate intrinsic value of exercised options for the three months ended February 28, 2019 was $0.08 million (2018 - $0.06 million). (b) Restricted Share Units and Deferred Share Units The Company has a Restricted Share Unit Plan (“RSU Plan”) and a Non-Executive Director Deferred Share Unit Plan (“DSU Plan”) to provide long-term incentives to employees, officers and directors. Awards under the RSU Plan and DSU Plan may be settled in cash and/or common shares of the Company at the Company’s election with each restricted share unit (“RSU”) and deferred share unit (“DSU”) entitling the holder to receive one common share of the Company or equivalent value. All units are accounted for as equity-settled awards. A summary of the Company’s unit plans and changes during the period ended February 28, 2019 is as follows: Number of RSUs Number of DSUs Balance – beginning of the period 400,002 1,182,106 Granted 225,000 10,746 Vested/paid (412,501 ) - Balance – end of period 212,501 1,192,852 For the period ended February 28, 2019, Trilogy recognized a stock-based compensation charge of $0.35 million (2018- $0.44 million), net of estimated forfeitures. As part of the annual incentive payout for the 2018 fiscal year, 225,000 RSUs were granted to officers, vesting half on the grant date and half on the first anniversary of the grant date. RSUs vesting in December 2018 were settled on December 21, 2018 through the issuance of 412,501 common shares. (c) Share Purchase Warrants A summary of the Company’s warrants and changes during the three months ended February 28, 2019 is as follows: Number of warrants Years to expiry Exercise price $ Balance – beginning of the period 6,521,740 0.59 1.52 Balance – end of period 6,521,740 0.34 1.52 |